Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?
Key takeaways
- LLY ^GSPC PFE NVDA Eli Lilly (NYSE: LLY) is basically hitting it out of the park right now.
- There s just one small problem for dividend investors: Eli Lilly s dividend yield is a tiny 0.6%.
- In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia.
LLY ^GSPC PFE NVDA Eli Lilly (NYSE: LLY) is basically hitting it out of the park right now. Sales of its industry-leading GLP-1 weight-loss drugs Mounjaro and Zepbound rose 125% and 80%, respectively, in the first quarter of 2026, driving a huge 56% sales gain for the drug giant. There s a reason why the stock is up more than 400% over the past five years.
There s just one small problem for dividend investors: Eli Lilly s dividend yield is a tiny 0.6%. That s well below the S&P 500 index s (SNPINDEX: ^GSPC) roughly 1% yield and the average drug stock s 1.6%. Eli Lilly competitor Pfizer (NYSE: PFE) has a 6.6% yield, which is more than 10x higher! Is it the better dividend stock?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »